Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Eli Lilly Stock Jumped Today

By Keith Speights - Dec 15, 2020 at 4:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big drugmaker upped its guidance for this year and announced a bullish outlook for 2021.

What happened

Shares of Eli Lilly ( LLY -0.93% ) jumped by 6% on Tuesday. The healthy gain came after the drugmaker raised its full-year 2020 revenue and earnings guidance, and provided a positive outlook for 2021. Lilly also announced plans to acquire Prevail Therapeutics ( PRVL )

So what

Investors love when a company's outlook improves. And Lilly's forecast looked better across the board.

Man wearing a coat and tie holding binoculars with dollar signs in the lenses

Image source: Getty Images.

The pharmaceutical giant now expects 2020 revenue of between $24.2 billion and $24.7 billion, up from the previous guidance range of  $23.7 billion to $24.2 billion. Management projects adjusted earnings per share for the year will be between $7.45 and $7.65, an increase from the prior range of $7.20 to $7.40.

Next year should be even better. Lilly anticipates 2021 revenue will be between $26.5 billion and $28 billion, with adjusted earnings per share of $7.75 to $8.40.

Lilly's optimism stems from the continuing sales growth within its strong product lineup. In particular, autoimmune disease drugs Olumiant and Taltz, diabetes drugs Trulicity and Jardiance, cancer drugs Cyramza, Retevmo, Tyvyt, and Verzenio, and migraine drug Emgality are enjoying tremendous momentum. Lilly also expects a revenue boost of between $1 billion and $2 billion from its COVID-19 therapies.

The acquisition of Prevail for a little over $1 billion could also prove to be a smart move. With the deal, Lilly will pick up Prevail's promising gene-therapy candidates, which target neurodegenerative diseases.

Now what

The big pharma stock doesn't appear to have any major roadblocks in sight. Its acquisition of Prevail hasn't been finalized yet, but will likely close in the first quarter of 2021. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$245.58 (-0.93%) $-2.30
Prevail Therapeutics Inc. Stock Quote
Prevail Therapeutics Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.